Cell Therapy
March Biosciences Receives FDA RMAT Designation for CAR-T Therapy Targeting Aggressive T-Cell Lymphoma
The FDA granted RMAT designation to March Biosciences' MB-105 CAR-T therapy for relapsed T-cell lymphoma, potentially accelerating treatment development for patients with limited survival options.
Creative Biolabs Accelerates CAR-T Therapy Innovation with Advanced Development Platform
Creative Biolabs is enhancing CAR-T therapy research through its comprehensive development platform, offering specialized viral vectors and ready-made plasmids that address critical challenges in scalability, cost, and technical efficiency for both blood cancers and emerging solid tumor applications.
Creative Biolabs Launches Integrated Cell Therapy Platforms to Advance Cancer Immunotherapy
Creative Biolabs has launched fully integrated CAR-T and TIL therapy development platforms, providing researchers and biotech startups with comprehensive services to accelerate the development of next-generation cellular immunotherapies for cancer treatment.
NanoCell Therapeutics' NCtx Platform Could Revolutionize CAR-T Therapy Accessibility
NanoCell Therapeutics' research demonstrates a novel method for in vivo CAR-T cell generation, potentially reducing costs and increasing access to life-saving cancer treatments.
Creative Biolabs Unveils Next-Generation CAR-T Engineering Platform for Smarter, Safer Cancer Therapy
Creative Biolabs introduces its Next CAR-T Engineering Platform, aiming to enhance the safety and efficacy of CAR-T cell therapy through advanced modular genetic programming and robust construct design.
Creative Biolabs Enhances Cell Therapy Research with Advanced iPSC and Macrophage Solutions
Creative Biolabs introduces innovative tools and services for iPSC neural differentiation and macrophage isolation, significantly advancing cell therapy research and disease modeling.
Beam Therapeutics to Unveil Promising Sickle Cell Disease Treatment Data at European Hematology Congress
Beam Therapeutics will present updated results from its BEACON trial for BEAM-101, an innovative ex vivo cell therapy targeting sickle cell disease, highlighting potential breakthrough treatment approaches at the European Hematology Association 2025 Congress.
Beam Therapeutics to Present Breakthrough Sickle Cell Disease Data at European Hematology Congress
Beam Therapeutics will reveal updated results from its BEACON trial on BEAM-101, an innovative ex vivo cell therapy targeting severe sickle cell disease, highlighting potential advances in genetic medicine treatment strategies.
Creative Biolabs Expands CAR-T Therapy Development with Comprehensive CDMO Services
Creative Biolabs is offering end-to-end solutions for CAR-T therapy development, providing comprehensive services from plasmid design to viral vector manufacturing, potentially accelerating personalized cancer treatment research.
Cellular Therapeutics Market Poised for Rapid Growth, Investors Eye Key Innovators
The global cell therapy market is projected to expand from $7.43 billion to $47.72 billion by 2034, with companies like Adia Nutrition, Fate Therapeutics, Pluri Inc., and Ginkgo Bioworks leading innovative developments in regenerative medicine and cellular technologies.
Creative Biolabs Advances CIK Cell Therapy Development for Cancer Treatment
Creative Biolabs offers comprehensive solutions for cytokine-induced killer (CIK) cell therapy development, potentially accelerating cancer immunotherapy research through advanced cellular isolation, expansion, and characterization techniques.